Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer

Lorraine Burke; Clare T. Butler; Adrian Murphy; Bruce Moran; William M. Gallagher; Jacintha O'Sullivan; Breandán N. Kennedy

doi:10.3389/fcell.2016.00103

Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer

Lorraine Burke, Clare T. Butler, Adrian Murphy, Bruce Moran, William M. Gallagher, Jacintha O'Sullivan, Breandán N. Kennedy

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

27 Scopus citations

Abstract

Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.

Original language	English (US)
Article number	103
Journal	Frontiers in Cell and Developmental Biology
Volume	4
Issue number	SEP
DOIs	https://doi.org/10.3389/fcell.2016.00103
State	Published - Sep 21 2016

Keywords

Colorectal cancer
Cysteinyl leukotriene
Cysteinyl leukotriene receptor antagonist
Eicosanoid
Hallmarks of cancer
Tumorigenesis

ASJC Scopus subject areas

Developmental Biology
Cell Biology

Access to Document

10.3389/fcell.2016.00103

Cite this

@article{f836f0b864ac44789c164c55b09ad65c,

title = "Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer",

abstract = "Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.",

keywords = "Colorectal cancer, Cysteinyl leukotriene, Cysteinyl leukotriene receptor antagonist, Eicosanoid, Hallmarks of cancer, Tumorigenesis",

author = "Lorraine Burke and Butler, {Clare T.} and Adrian Murphy and Bruce Moran and Gallagher, {William M.} and Jacintha O'Sullivan and Kennedy, {Breand{\'a}n N.}",

note = "Publisher Copyright: {\textcopyright} 2016 Burke, Butler, Murphy, Moran, Gallagher, O'Sullivan and Kennedy.",

year = "2016",

month = sep,

day = "21",

doi = "10.3389/fcell.2016.00103",

language = "English (US)",

volume = "4",

journal = "Frontiers in Cell and Developmental Biology",

issn = "2296-634X",

publisher = "Frontiers Media S. A.",

number = "SEP",

}

TY - JOUR

T1 - Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer

AU - Burke, Lorraine

AU - Butler, Clare T.

AU - Murphy, Adrian

AU - Moran, Bruce

AU - Gallagher, William M.

AU - O'Sullivan, Jacintha

AU - Kennedy, Breandán N.

PY - 2016/9/21

Y1 - 2016/9/21

N2 - Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.

AB - Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.

KW - Colorectal cancer

KW - Cysteinyl leukotriene

KW - Cysteinyl leukotriene receptor antagonist

KW - Eicosanoid

KW - Hallmarks of cancer

KW - Tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=84991658377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991658377&partnerID=8YFLogxK

U2 - 10.3389/fcell.2016.00103

DO - 10.3389/fcell.2016.00103

M3 - Short survey

AN - SCOPUS:84991658377

SN - 2296-634X

VL - 4

JO - Frontiers in Cell and Developmental Biology

JF - Frontiers in Cell and Developmental Biology

IS - SEP

M1 - 103

ER -

Evaluation of Cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this